E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036417 |
E.1.2 | Term | Postpartum haemorrhage |
E.1.2 | System Organ Class | 10036585 - Pregnancy, puerperium and perinatal conditions |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to compare efficacy of IV high single dose infusion of iron isomaltoside 1000 to standard medical care in women with PPH evaluated as physical fatigue. |
|
E.2.2 | Secondary objectives of the trial |
The secondary efficacy objectives of the study are to evaluate the effect of iron isomaltoside 1000 compared to standard medical care on
• Ability to increase Hb
• Other relevant iron and RBC related biochemical parameters
• Other fatigue symptoms
• Symptoms of postpartum depression
• Time of postpartum lactogenesis
• Time of discontinuation of breastfeeding
• Transfusion of allogenic RBCs
The safety objective of the study is to evaluate the safety of iron isomaltoside 1000 compared to standard medical care by
• Discontinuation due to intolerance
• Adverse events (AEs)
• Vitals signs
• Biochemical safety parameters
Other objectives
• Validation of the postpartum questionnaire
• Maternal milk iron level
• Anaemia and gastrointestinal symptoms
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
A subject will be eligible for inclusion in the study if they fulfil the following criteria:
1. Women with PPH ≥ 700 and ≤ 1000 mL or PPH > 1000 mL and Hb > 6.5 g/dL (4.0 mmol/L) measured > 12 hours after delivery
2. Willingness to participate and signed the informed consent form
|
|
E.4 | Principal exclusion criteria |
A subject will NOT be eligible for inclusion in this study if they fulfil any of the following criteria:
1. Women aged < 18 years
2. Multiple births
3. Peripartum RBC transfusion
4. Known iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)
5. Known hypersensitivity to parenteral iron or any excipients in the investigational drug products
6. Women with a history of active asthma within the last 5 years or a history of multiple allergies
7. Known decompensated liver cirrhosis or active hepatitis
8. Women with HELLP (Haemolysis Elevated Liver enzymes Low Platelet count) syn-drome (defined according to Dansk Selskab for Obstetrik og Gynækologi guidelines)
9. Active acute infection assessed by clinical judgement
10. Rheumatoid arthritis with symptoms or signs of active joint inflammation
11. Participation in any other clinical study where the study drug has not passed 5 half-lives prior to the baseline
12. History of anaemia caused by e. g. thalassemia, hypersplenism or haemolytic anaemia (known haematologic disorder other than iron deficiency)
13. Not able to read, speak and understand the Danish language
14. Any other medical condition that, in the opinion of the Investigator, may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from being in the study. For example, a malignancy, uncontrolled hypertension, un-stable ischaemic heart disease or uncontrolled diabetes mellitus
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of the study is to measure and compare the change in physical fatigue score from baseline to week 12 in the two treatment arms measured by the Multidimensional Fatigue Inventory (MFI) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints are to measure and compare the following in the two treatment arms
• Change in Hb concentration from baseline to week 1, 3, 8 and 12
• Proportion of women who achieve or maintain Hb levels of > 10 g/dL (6.2 mmol/L) at any time
• Proportion of women who achieve increase from baseline in Hb concentration ≥ 2.0 g/dL (1.2 mmol/L) at any time
• Proportion of women with decrease from baseline in Hb concentration ≥ 2.0 g/dL (1.2 mmol/L) at any time
• Change in concentrations of p-ferritin, p-iron, p-transferrin, transferrin saturation (TSAT), reticulocyte count, and mean reticulocyte haemoglobin content (CHr) from baseline to day 3, week 1, 3, 8 and 12
• Change in MFI physical fatigue symptoms from baseline to day 3, week 1, 3, 8 and 12
• Change in other MFI fatigue symptoms from baseline to day 3, week 1, 3, 8 and 12
• Change in postpartum depression symptoms measured by the Edinburgh Postnatal Depression Scale (EPDS) from week 1 to week 3, 8 and 12
• The amount of days from delivery to the day of postpartum lactogenesis
• The amount of days from delivery to the day of discontinuation of breastfeeding
• Proportion of women who has received 1 or more allogenic RBC transfusions and the number of units of RBC transfused per transfused patient during the study
Safety endpoints
• Proportion of women who discontinue from the study because of lack of response or intolerance of investigational drugs
• Type and incidence of adverse drug reactions (ADRs) including any suspected unex-pected serious adverse events (SUSAR)
• Number of AEs of special interest (i.e. hypersensitivity reactions or hypotension at pre-specified time points in relation to administration of study drug)
• Change in haematology parameters, p-sodium, p-potassium, p-calcium, p-phosphate, p-urea, p-creatinine, p-albumin, p-bilirubin, Aspartate Aminotransferase (ASAT), and Alanine Aminotransferase (ALAT) from baseline to day 3, week 1, 3, 8 and 12
Other endpoints
• Validation of the postpartum questionnaire at baseline, day 3, week 1, 3, 8 and 12
• Maternal milk iron level at day 3 and week 1
• Change in anaemia and gastrointestinal symptoms from day 3 to week 1, 3, 8 and 12
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 10 |